Skip to main content

Table 5 Comparison between HHT patients with ascertained SarsCov-2 infection vs. COVID-19-free patients

From: Characterization of epidemiological distribution and outcome of COVID-19 in patients with hereditary hemorrhagic telangiectasia: a nationwide retrospective multi-centre study during first wave in Italy

 

Ascertained COVID (n = 9)

Non COVID (n = 287)

p value

General (n = 296)

Age years-old, mean (SD)

46.22 (9.55)

53.15 (17.78)

0.25

Range

35–65

3–86

 

Gender (female), n (%)

3 (33.3)

154

0.31

Clinical, HHT-related (n = 296)a

Epistaxis, n (%)

9/9 (100)

274/287 (95.5)

1

PAVMs, n (%)

2/9 (22.2)

98/270 (36.3)

0.5

BAVMs, n (%)

0

27/226 (11.9)

0.4

HAVMs, n (%)

2/9 (22.2)

102/266 (38.3)

1

GI bleeding, n (%)

1/9 (11.1)

51/287 (17.8)

1

Mutated gene (n = 296)

Identified Mutation, n (%)

9 (100)

227 (79.1)

0.13

 ENG

3 (33.3)

83 (29)

 

 ALK1/ACVRL1

6 (66.7)

143 (49.8)

 

 SMAD4

0

1 (0.3)

 

Mutation unidentified/Ongoing analysis, n (%)

0

60 (20.9)

 
  1. aThe presence of HHT-related visceral arterio-venous malformations was computed by considering only those patients with screening performed in each given organ
  2. BAVMs brain arterio-venous malformations, HAVMs hepatic arterio-venous malformations, PAVMs pulmonary arterio-venous malformations